Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| NVVE | Nuvve | $3.57 | $1.37 | 62.27% | 30.1M | $2.9M | $1.98$200.80 |
| SMX | Smx (Security Matters) Public | $30.00 | $10.72 | 55.60% | 2.9M | $20M | $3.12$34,234.80 |
| GLUE | Monte Rosa Therapeutics | $24.10 | $8.09 | 50.53% | 439.7K | $1.0B | $3.50$25.14 |
| MNTS | Momentus | $13.84 | $4.01 | 40.79% | 11.7M | $14M | $4.73$160.65 |
| VTYX | Ventyx Biosciences | $13.81 | $3.76 | 37.41% | 719.3K | $717M | $0.78$25.00 |
| NMRA | Neumora Therapeutics | $2.42 | $0.60 | 32.69% | 6.8M | $304M | $0.61$3.25 |
| RGC | Regencell Bioscience | $41.36 | $8.33 | 25.22% | 35.2K | $16B | $0.09$83.60 |
| EUDA | Euda Health | $2.79 | $0.51 | 22.37% | 273.6K | $86M | $1.03$4.50 |
| LINT | Direxion Shares ETF Trust - Direxion Daily Intc Bull 2x ETF | $39.20 | $7.03 | 21.85% | 32.1K | - | $23.87$39.71 |
| ABVE | Above Food Ingredients | $2.13 | $0.34 | 19.00% | 2.7M | $92M | $0.25$6.56 |
Related Articles
Featured Article
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
Why Rezolve AI Stock Was a Scorcher in September
Eric Volkman|Oct 7, 2025
Investors tended to focus on the positive during the month.
Is Crinetics Pharmaceuticals Stock a Buy?
George Budwell, PhD|Sep 28, 2025
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.
Advertisement
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
Alex Carchidi|Sep 19, 2023
Despite good results in phase 3 trials, there are barriers to its drug candidate's success.
Is This Soaring Growth Stock a Buy?
Prosper Junior Bakiny|Nov 20, 2022
The answer may depend on your risk tolerance.
1 Beaten-Down Stock That Could Soar
Prosper Junior Bakiny|Jul 16, 2022
Will this biotech's recent rebound last?
2 Stocks Under $20 That Could Double Your Money
Prosper Junior Bakiny|May 27, 2022
These two companies have gotten quite the haircuts in recent months.
Could This New Partnership Help Realogy Grow Its Bottom Line?
Matt Frankel, CFP and Jason Hall|Dec 16, 2021
The real estate brokerage giant is teaming up with a big luxury brand.
This High-Risk, High-Reward Stock Might Double Your Money
Prosper Junior Bakiny|Oct 20, 2021
After a difficult year, shares of this biotech could bounce back big.
Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?
Keith Speights and Brian Orelli, PhD|Aug 26, 2021
More data is needed.
